Bethea D, Fullmer B, Syed S, Seltzer G, Tiano J, Rischko C, Gillespie L, Brown D, Gasparro F P
Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
J Dermatol Sci. 1999 Feb;19(2):78-88. doi: 10.1016/s0923-1811(98)00064-4.
In 1998 it is appropriate to commemorate the 50th anniversary of el Mofty's use of purified 8-methoxypsoralen (8-MOP) in the treatment of vitiligo (el Mofty AM. A preliminary clinical report on the treatment of leukoderma with Ammi majus linn. J R Egypt Med Assn 1948,31:651 65. el Mofty AM, el Sawalhy H, el Mofty M. Clinical study of a new preparation of 8-methoxypsoralen in photochemotherapy. Int J Dermatol 1994;8:588 92). Two young American dermatologists (Aaron Lerner and Thomas Fitzpatrick) were intrigued by the potency of this material. After Lerner determined that artificial long wavelength ultraviolet (320-400 nm, UVA) radiation was the most efficient for activating 8-MOP. the development of artificial sources enabled the efficient delivery of these photons to skin containing 8-MOP. Their initial studies for vitiligo led to further development of this therapy for the treatment of psoriasis (Parrish JA, Fitzpatrick TB, Tannenbaum L, et al. Photochemotherapy of psoriasis with oral methoxsalen and long-wave ultraviolet light. New Engl J Med 1974;291:1207-11. Honigsmann H, Fitzpatrick TB, Pathak MA, et al. Oral photochemotherapy with psoralen and UVA (PUVA): principles and practice. In: Fitzpatrick TB, Eisen AZ, Wolf K, editors. Dermatology in General Medicine. New York: McGraw-Hill, 1987:1728-54). This photochemotherapy came to be called 'PUVA' (psoralen + UVA). The position PUVA holds today as one of the most common procedures performed in dermatology can be traced to their initial curiosity and their subsequent ingenuity. Further developments in more recent years capitalized on their seminal work. The therapy met with unprecedented success from the outset, leaving little perceived need to understand underlying science. However, in recent years there has been a new found interest in the basic aspects of psoralen photobiology and molecular mechanistic events contributing to therapeutic responses as well as to the development of skin cancers in PUVA patients. These will be surveyed in this review commemorating the 50 years of modern psoralen photobiology and photomedicine.
1998年，适逢埃尔·莫夫蒂（el Mofty）使用纯化的8-甲氧基补骨脂素（8-MOP）治疗白癜风50周年，值得纪念（el Mofty AM. 关于用大阿美（Ammi majus linn.）治疗白斑病的初步临床报告。《埃及医学协会杂志》1948年，31:651 - 65。el Mofty AM，el Sawalhy H，el Mofty M. 8-甲氧基补骨脂素一种新制剂在光化学疗法中的临床研究。《国际皮肤病学杂志》1994年；8:588 - 92）。两位年轻的美国皮肤科医生（亚伦·勒纳（Aaron Lerner）和托马斯·菲茨帕特里克（Thomas Fitzpatrick））被这种物质的效力所吸引。在勒纳确定人工长波紫外线（320 - 400纳米，UVA）辐射是激活8-MOP最有效的方法后，人工光源的发展使得这些光子能够有效地传递到含有8-MOP的皮肤。他们最初针对白癜风的研究促使这种疗法进一步发展用于治疗银屑病（帕里什（Parrish JA），菲茨帕特里克（Fitzpatrick TB），坦嫩鲍姆（Tannenbaum L）等。口服甲氧沙林和长波紫外线治疗银屑病的光化学疗法。《新英格兰医学杂志》1974年；291:1207 - 11。霍尼格斯曼（Honigsmann H），菲茨帕特里克（Fitzpatrick TB），帕塔克（Pathak MA）等。补骨脂素和UVA（PUVA）口服光化学疗法：原理与实践。载于：菲茨帕特里克（Fitzpatrick TB），艾森（Eisen AZ），沃尔夫（Wolf K）编。《普通医学皮肤病学》。纽约：麦格劳 - 希尔，1987:1728 - 54）。这种光化学疗法后来被称为“PUVA”（补骨脂素 + UVA）。PUVA如今在皮肤科成为最常用的治疗方法之一，其根源可追溯到他们最初的好奇心以及随后的创造力。近年来的进一步发展利用了他们的开创性工作。这种疗法从一开始就取得了前所未有的成功，几乎没有人认为有必要去了解其基础科学。然而，近年来人们对补骨脂素光生物学的基础方面以及导致治疗反应和PUVA患者皮肤癌发生的分子机制事件有了新的兴趣。在这篇纪念现代补骨脂素光生物学和光医学50年的综述中，将对这些内容进行概述。
